Anne Marie Queenan

List of Publications by Year
in descending order

29 papers	5,050 citations	304368 22 h-index	476904 29 g-index
30 all docs	30 docs citations	30 times ranked	4946 citing authors

#	Article	IF	Citations
1	Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. Vaccine, 2019, 37, 80-89.	1.7	12
2	Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-ProducingBordetella pertussisin Children, Philadelphia 2007â€“2014. Clinical Infectious Diseases, 2017, 64, 60-66.	2.9	12
3	The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines. Expert Review of Vaccines, 2014, 13, 1265-1270.	2.0	6
4	Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. International Journal of Antimicrobial Agents, 2013, 41, 1-4.	1.1	33
5	Pertactin-Negative Variants of Bordetella pertussis in the United States. New England Journal of Medicine, 2013, 368, 583-584.	13.9	95
6	Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptibleAcinetobacter baumanniiisolates from nosocomial pneumonia patients. Journal of Chemotherapy, 2013, 25, 141-147.	0.7	5
7	Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagnostic Microbiology and Infectious Disease, 2012, 73, 267-270.	0.8	67
8	Detection of 2 SME-1 carbapenemase-producing Serratia marcescens in Detroit. Diagnostic Microbiology and Infectious Disease, 2011, 71, 325-326.	0.8	10
9	Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007â€“09. Journal of Antimicrobial Chemotherapy, 2011, 66, 2298-2307.	1.3	91
10	Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole. Antimicrobial Agents and Chemotherapy, 2010, 54, 4092-4097.	1.4	25
11	Hydrolysis and Inhibition Profiles of Î²-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem. Antimicrobial Agents and Chemotherapy, 2010, 54, 565-569.	1.4	89
12	New Variant of CTX-M-Type Extended-Spectrum Î²-Lactamases, CTX-M-71, with a Gly238Cys Substitution in a K lebsiella pneumoniae Isolate from Bulgaria. Antimicrobial Agents and Chemotherapy, 2009, 53, 4518-4521.	1.4	14
13	Effect of MexXY Overexpression on Ceftobiprole Susceptibility in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2009, 53, 2785-2790.	1.4	33
14	VIM-15 and VIM-16, Two New VIM-2-Like Metallo-Î²-Lactamases in Pseudomonas aeruginosa Isolates from Bulgaria and Germany. Antimicrobial Agents and Chemotherapy, 2008, 52, 2977-2979.	1.4	25
15	Interactions of Ceftobiprole with Î²-Lactamases from Molecular Classes A to D. Antimicrobial Agents and Chemotherapy, 2007, 51, 3089-3095.	1.4	84
16	Carbapenemases: the Versatile Î²-Lactamases. Clinical Microbiology Reviews, 2007, 20, 440-458.	5.7	2,068
17	Novel Carbapenem-Hydrolyzing Oxacillinase OXA-62 from Pandoraea pnomenusa. Antimicrobial Agents and Chemotherapy, 2006, 50, 1330-1335.	1.4	42
18	First Detection of Metallo-Î²-Lactamase VIM-2 in Pseudomonas aeruginosa Isolates from Colombia. Antimicrobial Agents and Chemotherapy, 2006, 50, 226-229.	1.4	28

#	Article	IF	Citations
19	CTX-M-15 extended-spectrum Î²-lactamase from Nigerian Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2006, 57, 24-30.	1.3	72
20	SME-3, a Novel Member of the Serratia marcescens SME Family of Carbapenem-Hydrolyzing Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2006, 50, 3485-3487.	1.4	42
21	Effects of Inoculum and Î²-Lactamase Activity in AmpC- and Extended-Spectrum Î²-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates Tested by Using NCCLS ESBL Methodology. Journal of Clinical Microbiology, 2004, 42, 269-275.	1.8	123
22	Biochemical Characterization of Î²-Lactamases Bla1 and Bla2 from Bacillus anthracis. Antimicrobial Agents and Chemotherapy, 2003, 47, 2040-2042.	1.4	60
23	Carbapenem-Resistant Strain of Klebsiella oxytoca Harboring Carbapenem-HydrolyzingÎ² -Lactamase KPC-2. Antimicrobial Agents and Chemotherapy, 2003, 47, 3881-3889.	1.4	172
24	TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum Î²-Lactamase Produced by a Clinical Isolate of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2002, 46, 2000-2003.	1.4	12
25	Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused byEscherichia coliandKlebsiella pneumoniaewith Reduced Susceptibility to Ceftazidime. Clinical Infectious Diseases, 2002, 34, 135-146.	2.9	131
26	Novel Carbapenem-Hydrolyzing Î²-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2001, 45, 1151-1161.	1.4	1,415
27	Cloning and Biochemical Characterization of FOX-5, an AmpC-Type Plasmid-Encoded Î²-Lactamase from a New York City Klebsiella pneumoniae Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2001, 45, 3189-3194.	1.4	42
28	Characterization of the Extended-Spectrum Î²-Lactamase Reference Strain, Klebsiella pneumoniae K6 (ATCC 700603), Which Produces the Novel Enzyme SHV-18. Antimicrobial Agents and Chemotherapy, 2000, 44, 2382-2388.	1.4	119
29	SME-Type Carbapenem-Hydrolyzing Class A Î²-Lactamases from Geographically Diverse Serratia marcescens Strains. Antimicrobial Agents and Chemotherapy, 2000, 44, 3035-3039.	1.4	123